Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)

The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Cytheris SA

Genexine Inc

GlaxoSmithKline Plc

OSE Immunotherapeutics

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Overview 6

Therapeutics Development 7

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Stage of Development 7

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Therapy Area 8

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Indication 9

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Companies 12

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Universities/Institutes 14

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies Involved in Therapeutics Development 23

Cytheris SA 23

Genexine Inc 24

GlaxoSmithKline Plc 25

OSE Immunotherapeutics 26

Pfizer Inc 27

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles 28

Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CYT-107 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

EFFI-7H - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

GSK-2618960 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

GX-I7 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PF-06342674 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Projects 37

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued Products 39

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Featured News & Press Releases 40

Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine 40

Jun 12, 2013: GSK Halts Clinical Trials Of Multiple Sclerosis Drug GSK-2618960 After Fraud Claim 40

Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leucoencephalopathy 41

Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation 41

Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy 42

Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients 43

Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Nonresponders To Standard Of Care 44

Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting 46

May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions 47

May 11, 2011: Cytheris, Lyon And ImmunID Announce Initiation Of Phase IIa Combination Trial Of IL-7 And XELODA In Metastatic Breast Cancer Treatment 48

Mar 01, 2011: Cytheris Announces Results From Phase IIa Study Of CYT107 50

Dec 07, 2010: Cytheris Announces Interim Phase I Study Results Of CYT107 In Treatment Of Post-Transplant Patients 51

Nov 08, 2010: Cytheris' ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention And Antiretroviral Intensification To Attack Viral Reservoir Of HIV Patients 53

Oct 19, 2010: Cytheris Initiates ORVACS-Sponsored Phase II Clinical Study To Attack Viral Reservoir Of HIV Patients 54

Sep 23, 2010: Cytheris Initiates Phase II Clinical Trial Of CYT107 In Chronically Infected HIV Patients 55

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Cytheris SA, H2 2016 23

Pipeline by Genexine Inc, H2 2016 24

Pipeline by GlaxoSmithKline Plc, H2 2016 25

Pipeline by OSE Immunotherapeutics, H2 2016 26

Pipeline by Pfizer Inc, H2 2016 27

Dormant Projects, H2 2016 37

Dormant Projects (Contd..1), H2 2016 38

Discontinued Products, H2 2016 39

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports